The Full Comparison
Semaglutide
GLP-1 Receptor Agonist
Mimics the GLP-1 hormone, which regulates appetite and blood sugar by slowing stomach emptying, reducing hunger signals, and influencing the brain's reward pathways associated with food.
Ozempic (diabetes) · Wegovy (weight loss)
12–15% of body weight (STEP clinical trials)
Weekly subcutaneous injection · titrated from 0.25 mg up to 2.4 mg (Wegovy) or 2 mg (Ozempic)
Nausea, diarrhea, vomiting, constipation, fatigue — most common during dose escalation
Available through licensed compounding pharmacies — significantly lower cost than brand name
Tirzepatide
Dual GLP-1 + GIP Receptor Agonist
Mimics both GLP-1 and GIP hormones simultaneously. The addition of GIP receptor activation may amplify metabolic effects and explain the higher average weight loss seen in clinical trials compared to semaglutide alone.
Mounjaro (diabetes) · Zepbound (weight loss)
15–22% of body weight (SURMOUNT clinical trials)
Weekly subcutaneous injection · titrated from 2.5 mg up to 15 mg
Nausea, diarrhea, vomiting, constipation — may be more pronounced initially due to dual mechanism
Available through licensed compounding pharmacies — significantly lower cost than brand name
Side-by-Side at a Glance
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP |
| Avg. weight loss | 12–15% | 15–22% |
| Injection frequency | Weekly | Weekly |
| FDA weight loss approval | Wegovy | Zepbound |
| Food noise reduction | Significant | Significant |
| Compounded available | Yes | Yes |
| Brand name cost (est.) | $1,000–$1,500/mo | $1,000–$1,500/mo |
| GI side effects | Common; individual tolerance varies | Common; individual tolerance varies |
| Long-term data | More established | Growing (newer drug) |
Which Should You Choose?
There is no universal answer — the right medication depends on your health history, how your body responds, and what your provider recommends after a clinical evaluation. That said, here are the general considerations:
Consider Semaglutide If:
- You have previously tolerated GLP-1 medications well
- You prefer a medication with more long-term clinical data
- Your provider recommends it based on your health history
- Tirzepatide is unavailable through your pharmacy
Consider Tirzepatide If:
- You are looking for the highest average weight loss results
- You have not responded adequately to semaglutide
- Your provider determines the dual mechanism may benefit your metabolic profile
- You are comfortable with a newer medication with growing safety data
Important: Both medications require a prescription from a licensed provider. South Florida Trim Clinic's providers evaluate every patient individually before making any recommendation. Book a free consultation to discuss which option may be right for you.
Frequently Asked Questions
Which is more effective — semaglutide or tirzepatide?
Clinical trials show tirzepatide generally produces greater average weight loss — approximately 15–22% of body weight versus 12–15% for semaglutide. However, individual results vary significantly, and some patients respond better to semaglutide. A licensed provider can help evaluate which option may be more appropriate for your health history.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist — it mimics the GLP-1 hormone that regulates appetite and blood sugar. Tirzepatide is a dual GLP-1 and GIP agonist — it targets both GLP-1 and GIP hormone receptors, which may explain its stronger average weight loss results in clinical trials.
Which medication has fewer side effects?
Both FDA labels list nausea, diarrhea, constipation and vomiting. Symptoms and tolerability vary by person. The sources here do not establish that the dual mechanism itself causes worse early side effects; rates from separate trials are not head-to-head comparisons.
Can I switch from semaglutide to tirzepatide?
Yes, under medical supervision. A licensed provider would evaluate your health history, your response to current medication, and help determine if switching is medically appropriate for you.
Which medication does South Florida Trim Clinic prescribe?
South Florida Trim Clinic's licensed providers prescribe both semaglutide and tirzepatide when clinically appropriate. Your provider determines the right option based on your individual health history, goals, and eligibility.
Are semaglutide and tirzepatide available as compounded medications?
Compounded drugs are not FDA-approved and are not established as equivalent to approved products. Their use depends on patient-specific medical need and current legal requirements, not simply a lower price. Discuss approved alternatives and risks with your prescriber and pharmacist.
Get the Right Medication for You
A licensed provider will review your health history and help you determine which medication — and which program — is the best fit.
MEDICAL SOURCES & FURTHER READING
Check the source and its limits. The notes below explain which medical information each reference supports; they are not patient-specific advice or evidence of this clinic's results.
- Wegovy (semaglutide) injection — prescribing information
Sections 1–6 and the Medication Guide cover eligibility, dose escalation, GLP-1 action, gastrointestinal effects, thyroid-tumor warnings, pancreatitis, gallbladder disease, volume depletion and pregnancy precautions.
Evidence limits: This dated label is for FDA-approved Wegovy injection. Follow the current label for your specific product and your prescriber's instructions; it does not establish the safety or effectiveness of a compounded preparation.
- Zepbound (tirzepatide) injection — prescribing information
Sections 1–6 and 12 describe GIP/GLP-1 receptor activity, eligibility, gradual dose escalation, common adverse reactions, contraindications and important safety warnings. Section 8 addresses pregnancy and oral contraceptive precautions.
Evidence limits: Applies to the approved Zepbound product, not every tirzepatide preparation. Trial adverse-event frequencies are product- and population-specific.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Research published in the New England Journal of Medicine reported greater average weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo plus lifestyle intervention over 68 weeks in adults without diabetes. Nausea and diarrhea were common adverse events.
Evidence limits: A randomized trial of a defined dose/product and selected population, funded by Novo Nordisk. Not a clinic outcome, first-month forecast, or guarantee; results do not transfer automatically to compounded products.
- Tirzepatide Once Weekly for the Treatment of Obesity
Research published in the New England Journal of Medicine reported sustained average weight reduction with tirzepatide over 72 weeks in adults with obesity or overweight and a weight-related complication, without diabetes.
Evidence limits: SURMOUNT-1 was funded by Eli Lilly. It was not a direct comparison with semaglutide; different trials cannot predict which medicine is best for an individual.
- Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Compounding may address a patient-specific medical need but carries quality and dosing risks.
RESEARCH & REFERENCES
- Wegovy (semaglutide) injection — prescribing information
U.S. Food and Drug Administration. FDA product labeling. 2025.
Read Wegovy (semaglutide) injection — prescribing information - Zepbound (tirzepatide) injection — prescribing information
U.S. Food and Drug Administration. FDA product labeling. 2026.
Read Zepbound (tirzepatide) injection — prescribing information - Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding and colleagues. New England Journal of Medicine. 2021.
Read Once-Weekly Semaglutide in Adults with Overweight or Obesity - Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff and colleagues. New England Journal of Medicine. 2022.
Read Tirzepatide Once Weekly for the Treatment of Obesity - Understanding the Risks of Compounded Drugs
U.S. Food and Drug Administration. FDA patient safety information. Web resource; accessed 2026.
Read Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded preparations are not established as equivalent to FDA-approved products. Patient-specific need and applicable compounding requirements must be evaluated by the prescriber and pharmacy.
These independent information sources do not endorse, sponsor or affiliate with South Florida Trim Clinic. Education is not a substitute for individualized medical advice. Prescription treatment requires evaluation by an appropriately licensed healthcare provider.